Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2012
11/06/2012CA2489208C Interleukin-6 suppressive agent
11/06/2012CA2450939C Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
11/06/2012CA2302743C Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces
11/01/2012WO2012149566A2 Anti-hiv group i introns and a uses thereof in treating hiv infections
11/01/2012WO2012148891A1 Peptide-lipid conjugates and uses thereof
11/01/2012WO2012148720A2 Anti-microbial peptides and methods of use thereof
11/01/2012WO2012148295A1 Antiviral drug derivative
11/01/2012WO2012147773A1 Novel cephem compound having catechol or pseudo-catechol structure
11/01/2012WO2012147327A1 Pandemic influenza antiviral agent
11/01/2012WO2012147056A1 Vaginal composition based on alkyl polyglucosides
11/01/2012WO2012146099A1 Intermediate for synthesizing caspofungin and preparation method therefor
11/01/2012WO2012145981A1 Adamantane or adamantane-like compounds as antitumor agents
11/01/2012WO2012145946A1 Application of dwarf lilyturf tuber polysaccharide extract in preparation of dietary supplement, health food or medicine with the function of weight loss
11/01/2012WO2012145801A1 Nanoparticle
11/01/2012WO2012104874A3 Aqueous concentrated formulation of linezolid
11/01/2012WO2012083138A3 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
11/01/2012WO2012078637A3 Composition and method for oligonucleotide delivery
11/01/2012WO2011140202A3 Mif modulators
11/01/2012WO2011086134A9 Treatment of chlamydiaceae infections by means of beta-lactams
11/01/2012US20120277772 Hppe yarns
11/01/2012US20120277693 Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
11/01/2012US20120277315 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
11/01/2012US20120277312 Ethylgallate and Related Compounds as a Treatment for Sepsis and Septic Shock
11/01/2012US20120277289 Activity generating delivery molecules
11/01/2012US20120277279 Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions
11/01/2012US20120277266 Hepatitis C Virus Inhibitors
11/01/2012US20120277263 Polymorphs of 1-cyclopropyl-7-([s,s])-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro -8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
11/01/2012US20120277252 Antibacterial Agents and Methods of Use Thereof
11/01/2012US20120277249 Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
11/01/2012US20120277248 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
11/01/2012US20120277240 Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
11/01/2012US20120277219 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
11/01/2012US20120277214 Tricyclopyrazole derivatives
11/01/2012US20120277207 Novel heterocyclic acrylamides and their use as pharmaceuticals
11/01/2012US20120277206 Reverse transcriptase inhibitors
11/01/2012US20120277198 Polyhydroxylated bile acids for treatment of biliary disorders
11/01/2012US20120277197 Tigecycline formulations
11/01/2012US20120277193 Synergistic Combination Therapy
11/01/2012US20120277191 Forms of cidofovir
11/01/2012US20120277187 Agent for Preventing Infection
11/01/2012US20120277184 Blockers of pore-forming virulence factors and their use as anti-infectives
11/01/2012US20120277177 Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-beta-ribofuranosyl-1h-benzimidazole
11/01/2012US20120277172 Carbohydrate-lipid constructs and their use in preventing or treating viral infection
11/01/2012US20120277146 Compounds For Enzyme Inhibition
11/01/2012US20120277145 Compounds
11/01/2012US20120276223 Composition for preventing and treating influenza-virus-induced diseases
11/01/2012US20120276220 Method of Treating Hepatitis
11/01/2012US20120276217 Disinfecting formulation
11/01/2012US20120276215 Therapeutic Conditioned Media
11/01/2012US20120276201 Compositions and method for treatment and prophylaxis of inflammatory bowel disease
11/01/2012US20120276192 Compositions and methods for sirna inhibition of icam-1
11/01/2012US20120276191 Treatment and Diagnosis of Macrophage Mediated Disease
11/01/2012US20120276175 Personal Cleansing Compositions with Increased Deposition of Polyacrylate Microcapsules
11/01/2012US20120276167 Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
11/01/2012US20120276153 Use of aerosolized levofloxacin for treating cystic fibrosis
11/01/2012US20120276149 Methods for modulating bacterial infection
11/01/2012US20120276145 Extracellular matrix proteins from haemophilus influenzae biofilms: targets for therapeutic or diagnostic use
11/01/2012US20120276144 Pro-Apoptotic Bacterial Vaccines To Enhance Cellular Immune Responses
11/01/2012US20120276143 Probiotic bifidobacterium strain
11/01/2012US20120276139 Use of newcastle disease virus-based vector for inducing an immune response in mammals
11/01/2012US20120276138 Rapid and prolonged immunologic-therapeutic
11/01/2012US20120276137 Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
11/01/2012US20120276132 Atoxic recombinant holotoxins of Clostridium difficile as immunogens
11/01/2012US20120276130 Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
11/01/2012US20120276128 HIV Envelope-CD4 Complexes and Hybrids
11/01/2012US20120276115 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
11/01/2012US20120276108 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
11/01/2012US20120276107 Methods and Compositions for Mycoplasma Pneumoniae Exotoxins
11/01/2012US20120276101 Viral chemokine-antigen fusion proteins
11/01/2012US20120276075 Synergic action of a prolyl protease and tripeptidyl proteases
11/01/2012US20120276074 Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
11/01/2012US20120276071 Anti-HIV Group I Introns and Uses Thereof in Treating HIV Infections
11/01/2012US20120276056 Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
11/01/2012US20120276054 Alternative bacterial treatment
11/01/2012US20120276050 Methods and compositions of treating a flaviviridae family viral infection
11/01/2012US20120276049 Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
11/01/2012US20120276047 Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
11/01/2012US20120275996 IL-1 Binding Proteins
11/01/2012CA2837367A1 Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
11/01/2012CA2834400A1 Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease
11/01/2012CA2834376A1 Neutralizing antibodies to nipah and hendra virus
11/01/2012CA2834353A1 Liposomal vancomycin for the treatment of mrsa infections
11/01/2012CA2833206A1 Intermediate for synthesizing caspofungin and preparation method therefor
11/01/2012CA2833121A1 Novel cephem compound having catechol or pseudo-catechol structure
11/01/2012CA2833115A1 Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
11/01/2012CA2819632A1 Vaginal composition based on alkyl polyglucosides
10/2012
10/31/2012EP2518073A1 Compounds for the treatment of Hepatitis C
10/31/2012EP2517726A2 Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
10/31/2012EP2517716A1 Oral compositions containing botanical extracts
10/31/2012EP2517709A1 Medical and pharmaceutical use of 2', 2-bis-thiazole non-nucleoside compounds as hepatitis c virus inhibitor
10/31/2012EP2516645A1 Influenza targets
10/31/2012EP2516442A1 Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds
10/31/2012EP2516422A1 Extracts from kibdelos porangium as antibacterial agents
10/31/2012EP2516405A1 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
10/31/2012EP2516393A1 Carboxamide compounds and their use as calpain inhibitors
10/31/2012EP2516387A2 New inhibitors of cyclophilins and uses thereof
10/31/2012EP2516008A1 Novel antiviral compounds
10/31/2012EP2515940A1 Immunogenic compositions and related methods
10/31/2012EP2515938A1 Immunogenic compositions
10/31/2012EP2515935A1 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
1 ... 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 ... 1798